E.g., 10/28/2020
E.g., 10/28/2020

bioMérieux launches Predictive Diagnostics, pairing microbiology solutions with data science, sequencing and predictive modeling

26 October, 2020

Predictive Diagnostics uses traditional core microbiology solutions alongside data science, sequencing applications and predictive modeling to help move food producers from being reactive to being proactive.

10 Organizations Across U.S. Receive Over €3 Million From bioMérieux

12 October, 2020

Due to the significant economic and social consequences presented by the COVID-19 pandemic, bioMérieux has decided to distribute 50% of its 2019 dividend as corporate philanthropy to support charitable initiatives around the world.

Mérieux NutriSciences EnviroMap Collaborates with bioMérieux, Inc.

04 September, 2020

Mérieux NutriSciences collaborates with bioMérieux, Inc. to deliver EnviroMap® to the food industry.

bioMérieux Receives Emergency Use Authorization for Its VIDAS® SARS-CoV-2 Antibody Serology Tests

07 August, 2020

bioMérieux has received Emergency Use Authorization by the U.S. Food and Drug Administration of its VIDAS® SARS-COV-2 IgM and VIDAS® SARS-COV-2 IgG serology tests.

bioMérieux Continues to Win Numerous Industry Awards for Outstanding Service and Performance

21 July, 2020

bioMérieux has recently been recognized with six IMV ServiceTrak™ Clinical awards for Blood Culture and ID/AST excellence.

Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products

16 July, 2020

bioMérieux announces the launch of BIOFIRE® MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry.

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked

15 July, 2020

bioMérieux announced the CE marking of BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) tests for detection of 23 pathogens, including SARS-CoV-2.

bioMérieux 2019 Annual Report

13 July, 2020

In guiding the Company’s development, bioMérieux has always focused on meeting healthcare challenges related to infectious diseases all over the world. With over 90% of sales outside of France today, the scope of our activity is geographically balanced.

bioMérieux – Second-Quarter 2020 Business Performance Preannoucement

09 July, 2020

Marcy l'Étoile (France), July 9, 2020 – In light of the withdrawal of its annual objectives, bioMérieux, a world leader in the field of in vitro diagnostics, today announced preliminary quarterly information about its business activity ending June 30, 2020.

bioMérieux receives FDA clearance to extend platelet shelf life to 7 days with Large Volume Delayed Sampling strategy using BACT/ALERT® 3D and BACT/ALERT® VIRTUO® culture systems.

22 May, 2020

bioMérieux announces that its BACT/ALERT® BPA and BPN culture bottles have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Large Volume Delayed Sampling (LVDS) of leukocyte-reduced apheresis platelets (LRAP) and leukocyte-reduced whole blood platelet concentrates (LRWBPC) with BACT/ALERT®3D and BACT/ALERT® VIRTUO® systems.

Pioneering Diagnostics